Epilepsia Publishes Interim Results of Open-Label Extension Study of FINTEPLA® (fenfluramine) Oral Solution in Patients with Lennox-Gastaut Syndrome (LGS)

Peer-reviewed results from the Phase 3 open-label extension study of FINTEPLA® in LGS provide significant reduction in the frequency of multiple seizure types...

Related Keywords

Colorado ,United States ,Japan ,Brussels ,Bruxelles Capitale ,Belgium ,France ,Smyrna ,Izmir ,Turkey ,French ,Erica Puntel ,Kelly Knupp ,Antje Witte ,Group Of Companies ,Twitter ,Ucb Inc ,Zogenix Inc ,Program See Boxed Warning ,Euronext ,Associate Professor ,Hospital Colorado ,Mitigation Strategy ,Prescribing Information ,Boxed Warning ,Heart Disease ,Pulmonary Arterial Hypertension ,Decreased Weight ,Antiepileptic Drugs ,Blood Pressure ,Euronext Brussels ,Lennox Gastaut Syndrome ,Ucb ,